Coherus Oncology Reports Results for Quarter Ended June 30, 2026

What Happened
Coherus Oncology, Inc. announced its financial results for the quarter ended June 30, 2026 by issuing a press release dated August 5, 2026. The company furnished the full press release as Exhibit 99.1 to its Form 8-K (filed August 5, 2026) under Item 2.02 — Results of Operations and Financial Condition. The filing is signed by CEO Dennis M. Lanfear.

Key Details

• Form 8-K filed and dated August 5, 2026 (Item 2.02: Results of Operations and Financial Condition).
• Press release reporting the quarter ended June 30, 2026 was furnished as Exhibit 99.1.
• Filing signed by Chief Executive Officer Dennis M. Lanfear.
• No other material events (such as executive departures or mergers) were disclosed in this Form 8-K.

Why It Matters
This filing signals that Coherus has publicly released its quarterly earnings and related financial information; those results (revenue, profit/loss, and any commentary on operations or outlook) can influence the stock and investor decisions. Retail investors should read the furnished press release for the specific numbers and management commentary to assess short‑term performance and any implications for future guidance or valuation.